malaria – Medxy AI

Human Monoclonal Antibody MAM01 for Malaria Prevention: Phase 1 Trial Insights and Context in Antimalarial Monoclonal Antibody Development

By MedXY 11/23/2025

This review synthesizes evidence on MAM01, a monoclonal antibody targeting Plasmodium falciparum circumsporozoite protein, summarizing its first-in-human phase 1 trial demonstrating safety and protective efficacy, alongside contextual advances in monoclonal antibody-based malaria prevention.

Infectious Diseases news Public Health

GanLum (KLU156): A New Class of Antimalarial Showing 97.4% PCR‑Corrected Cure in Phase III

By MedXY 11/14/2025

A Phase III trial of ganaplacide‑lumefantrine (GanLum, KLU156) met its primary non‑inferiority endpoint vs artemether‑lumefantrine, with a PCR‑corrected Day‑29 cure rate of 97.4% (estimand). The drug combines a novel mechanism (ganaplacide) with once‑daily lumefantrine and shows promise against partially resistant strains and gametocytes.

Clinical Updates Family Medicine & Nutrition news Public Health Specialties

Seasonal Malaria Chemoprevention in Uganda: Efficacy of SPAQ and Dihydroartemisinin-Piperaquine in the Era of Drug Resistance

By MedXY 08/03/2025

A large cluster-randomised trial in Uganda demonstrates that both SPAQ and dihydroartemisinin-piperaquine are highly effective and safe for seasonal malaria chemoprevention in children, with no evidence of resistance selection.

Infectious Diseases Specialties

Mass Ivermectin Administration for Malaria Control: Translational Insights from Recent Cluster-Randomized Trials

By MedXY 07/31/2025

Recent cluster-randomized trials in Kenya and Burkina Faso provide mixed but informative evidence on the efficacy and safety of mass ivermectin administration for malaria control, highlighting both its potential and limitations.